参会/布展/演讲,早鸟报名中2025 年 7 月 28 日医麦客新闻 eMedClub News随着技术突破与资本入局,TCE 三抗领域呈现加速发展态势。一个百亿级赛道的序幕已然悄然揭开。近日,泽璟制药三抗ZG006拟纳入突破性治疗品种,用于治疗既往多线治疗失败的晚期小细胞肺癌(SCLC)。这款全球首个针对 DLL3 表达的 TCE 三抗手握中美双批的临床试验资格与 FDA 孤儿药认定。▲ CDE...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.